

In the Specification

Please amend the title of the International Patent Application to read as follows:

~~PLANT ORIGIN  $\beta_3$ -ADRENOCEPTOR AGONIST AND USE OF THE SAME~~  
PLANT-DERIVED  $\beta_3$ -ADRENERGIC RECEPTOR AGONIST SUBSTANCES AND USES  
THEREOF

Please add the following paragraph at page 1, above line 5 after the Title:

This application is a National Stage Application of International Application Number PCT/JP2004/016330, filed November 4, 2004; which claims priority to JP 2003-374836, filed November 4, 2003.

Please amend the specification at page 11, lines 8-22 as follows:

The obtained recombinant cells were cultured in a 96-well microplate until the cell density reaches 100%. After the medium was removed, the cells were washed once with Dulbecco's modified phosphate buffer solution (hereinafter, abbreviated as PBS; TaKaRa), and then 100  $\mu$ L of an assay buffer [DMEM, 10% FCS, 20 mM HEPES (pH 7.2), 0.1 mM isobutylmethylxanthine] containing 10  $\mu$ M isoproterenol was added. As a control, the assay buffer was used without addition of isoproterenol. After incubation at 37°C for 20 minutes, the cells were washed once with PBS, and then the amount of intracellular cAMP were quantified using a cAMP EIA Kit (Amersham Bioscience). The recombinant cells, in which the intracellular cAMP level had greatly increased because of the isoproterenol added as a  $\beta$ -

adrenergic receptor agonist, were selected. The selected recombinant cells were further cultured. After the cells were detached with trypsin, they were diluted with a culture medium and dispensed into a 96-well microplate at 1 cell per well. These cells were further cultured and their responsiveness to isoproterenol was confirmed with a similar procedure. Recombinant cells that showed good responsiveness were purified, and ultimately a single human  $\beta_3$ -adrenergic receptor-expressing recombinant, ~~6H-4d3~~ 6H4-2d3, was obtained.